Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NS Pharma, Inc.
With
Nippon Shinyaku Co., Ltd.
Age
4–15
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male ≥ 4 years and \<16 years of age;
Confirmed DMD exon deletion in the dystrophin gene that is amenable to skipping of exon 50 to restore the dystrophin mRNA reading frame;
Able to walk independently without assistive devices;
Able to complete the TTSTAND without assistance in \<20 seconds;
Stable dose of glucocorticoid for at least 3 months and the dose is expected to remain on a stable dose for the duration of the study.
You may not be if
Evidence of symptomatic cardiomyopathy;
Current or previous treatment with anabolic steroids (e.g., oxendolone, oxandrolone) or products containing resveratrol or adenosine triphosphate within 3 months prior to first dose of study drug;
Currently taking another investigational drug or has taken another investigational drug within 3 months prior to the first dose of study drug;
Surgery within the 3 months prior to the first dose of study drug or planned during the study duration;
Having taken any gene therapy.
Clareo Health | NS-050/NCNP-03 in Boys With DMD (Meteor50)
